placebo monotherapy

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, GlaxoSmithKline, Peking University Third Hospital

Conditions

Acquired Immunodeficiency SyndromeHIV InfectionsMemory ImpairmentParkinson Disease

Phase 2

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

CompletedNCT00100048

Merck Sharp & Dohme LLCAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2005-01-31End: 2010-07-31Updated: 2015-09-09

Phase 4

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

CompletedNCT01485172

GlaxoSmithKlineParkinson Disease

Start: 2012-01-31End: 2014-04-30Updated: 2018-06-20

Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease

Peking University Third HospitalMemory Impairment, Parkinson Disease

Start: 2018-01-01End: 2021-12-31Target: 150Updated: 2021-07-20

Related Papers

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

2007-10-01297 citations